Ori Biotech Signs 10-Year, $120M Deal to Move a Commercial Cell Therapy onto Its IRO Platform
核心洞察
Ori Biotech (搜索) will integrate its automated IRO platform (搜索) into an undisclosed biopharmaceutical partner's commercial autologous cell therapy (搜索) manufacturing process under a deal valued at up to $120 million over 10 years.
The collaboration aims to demonstrate comparability between the IRO process and the partner's existing commercial manufacturing process while building flexible, scalable supply infrastructure.
The IRO platform (搜索), which received FDA Advanced Manufacturing Technology designation in June 2025, combines hardware, consumables, software and data analytics in a closed, GMP-ready system.
Ori Biotech (搜索) has entered a strategic collaboration with an undisclosed biopharmaceutical company to integrate its IRO platform (搜索) into a commercial cell therapy manufacturing process, in a deal valued at up to $120 million in services, milestones, equipment and consumable purchases over the next 10 years.
The collaboration is designed to modernize the partner's autologous cell therapy (搜索) manufacturing infrastructure, with the stated aim of expanding patient access to current and future potentially transformative cell therapies. Autologous therapies, manufactured from a patient's own cells, require precise, reliable and scalable manufacturing processes — a requirement Ori describes as essential to sustaining commercial availability and to bringing the next generation of cell therapies to patients at scale.
A closed, GMP-ready system
The IRO platform (搜索) automates what the company calls "better biology" by combining proprietary hardware, consumables, software and data analytics in a closed, GMP-ready system. It is designed to support the full journey from R&D through commercial manufacturing on a single platform.
According to Ori, IRO addresses the core challenges of autologous cell therapy (搜索) production: reducing batch-to-batch variability, minimizing operator touch time, increasing throughput and lowering cost of goods, while improving the biological performance that often determines clinical outcomes. The platform received Advanced Manufacturing Technology designation from the US FDA (搜索) in June 2025.
"Our newest partner has made an important commitment to further advancing its cell therapy capabilities at a time when the field needs dedicated, patient-focused organizations to help bring these therapies to patients," said Jason C. Foster, CEO of Ori Biotech (搜索). "The IRO platform (搜索) was built precisely for this challenge: to give therapy developers the scalability, reproducibility and cost efficiency they need to realize both the clinical and commercial benefits of these groundbreaking therapies."
Comparability and commercial supply
Under the agreement, the two parties will work together to demonstrate comparability of the IRO process to the existing commercial manufacturing process. The objective is to build a flexible and scalable manufacturing infrastructure capable of supporting ongoing commercial supply as well as future development and commercialization needs.
Ori reports that IRO has been adopted by 23 partners since its launch in 2024. In May 2026, the platform reached a milestone with the dosing of the first patient treated with a therapy manufactured on IRO and released under GMP.
Broader momentum in automated cell therapy manufacturing
The Ori partnership was one of several developments in cell and gene therapy manufacturing this week. Cellares (搜索) has partnered with GenomeFrontier Therapeutics (搜索) to evaluate the potential to automate manufacturing of GF-CART01, GenomeFrontier's experimental CAR-T therapy, on Cellares' Cell Shuttle (搜索) platform.
That collaboration will focus on adapting GenomeFrontier's virus-free manufacturing process to the Cell Shuttle (搜索) system, with particular emphasis on the transfection step using Cellares (搜索)' proprietary integrated electroporator. It represents Cellares' first development partnership in Asia and is intended to support GenomeFrontier's clinical efforts in the United States as it advances GF-CART01.
"GenomeFrontier's virus-free approach reflects the increasing complexity of next-generation cell therapy manufacturing," said Fabian Gerlinghaus, co-founder and CEO of Cellares (搜索). "The Cell Shuttle (搜索) is built to automate complex processes, including electroporation-based workflows, with the scalability and reliability needed as therapies advance through clinical development."
The Cellares (搜索) announcement follows Bristol Myers Squibb (搜索)'s termination of its manufacturing agreement with the company last month. Bristol Myers Squibb determined that the Cell Shuttle (搜索) platform could not meet the commercial-scale manufacturing requirements for Breyanzi (lisocabtagene maraleucel), an assessment Cellares disputes.
Separately, the FDA cleared an Investigational New Drug application for Vyriad (搜索)'s in vivo CAR-T therapy VV169 (搜索), allowing the company to begin a Phase I trial in patients with relapsed or refractory multiple myeloma (搜索). VV169 uses an engineered lentiviral vector retargeted through VSV-G pseudotyping, a modification intended to specifically target and transduce T cells in the bloodstream with an anti-BCMA (搜索) CAR payload.
"VV169 (搜索) is designed to create CAR-T cells directly inside the body, offering a new way of delivering this powerful therapeutic approach to patients with multiple myeloma (搜索)," said Vyriad (搜索) president Luke Russell. The Phase I trial will primarily evaluate safety, identify dose-limiting toxicities and determine the recommended Phase II dose, with secondary objectives of assessing preliminary efficacy signals and evaluating in vivo CAR T cell expansion and persistence.